Abstract
Background:
Pioglitazone added to successful statin therapy may be beneficial for coronary artery disease (CAD) patients without diabetes mellitus.
Methods and results:
Fourteen individuals optimally treated with statin for >6 months were randomized to a pioglitazone or control group. Pioglitazone significantly improved insulin resistance, reduced high-sensitivity C-reactive protein, increased high-molecular-weight adiponectin and high-density lipoprotein cholesterol levels. Ultrasound echogenicity of carotid atheroma assessed by integrated backscatter was significantly increased by pioglitazone and correlated with adiponectin levels.
Conclusion:
Adding pioglitazone to successful statin therapy may be an effective therapeutic strategy for patients with CAD.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adiponectin / blood
-
Adiponectin / chemistry
-
Aged
-
C-Reactive Protein / metabolism
-
Carotid Artery Diseases / diagnostic imaging
-
Carotid Artery Diseases / drug therapy
-
Cholesterol, HDL / blood
-
Coronary Artery Disease / drug therapy*
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
-
Hypoglycemic Agents / administration & dosage*
-
Insulin Resistance
-
Male
-
Middle Aged
-
Molecular Weight
-
Pioglitazone
-
Thiazolidinediones / administration & dosage*
-
Treatment Outcome
-
Ultrasonography
Substances
-
ADIPOQ protein, human
-
Adiponectin
-
Cholesterol, HDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypoglycemic Agents
-
Thiazolidinediones
-
C-Reactive Protein
-
Pioglitazone